Association of Prenatal Exposure to Benzodiazepines With Development of Autism Spectrum, Attention-Deficit/Hyperactivity Disorders

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 22, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.43282?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=112222

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: Researchers found in this study of 1.5 million children that after adjusting for possible confounders and accounting for possible parental genetic or familial factors, benzodiazepine exposure during pregnancy was not associated with increased risks of autism spectrum disorder or attention-deficit/hyperactivity disorder. These results challenge current assumptions of a potential association of neurodevelopmental disorders with maternal benzodiazepine use before or during pregnancy. 

Authors: Yi-Lung Chen, Ph.D., of Asia University in Taichung, Taiwan, and Mong-Liang Lu, M.D., M.S., of Taipei Medical University in Taipei, Taiwan, are the corresponding authors. 

 

(doi:10.1001/jamanetworkopen.2022.43282)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.